You see, despite the fact that marijuana has proven to be beneficial for treating a wide range of medical conditions, professionals lack knowledge and therefore are hesitant to advise patients on treatment plans.

The Journal Of The American Board Of Family Medicine conducted a survey with 520 family physicians responding. Their results: 92% of family physicians surveyed believe that continuing medical marijuana education should be available to family physicians. In addition, 81% agreed that physicians should have formal training before recommending medical marijuana.

While doctors are able to approve or recommend—not prescribe—medical marijuana, federal law keeps them at arm’s length in terms of actually providing any assistance to the patient

- Liz McDuffie,

Director of Medical Cannabis Caregivers,
in an interview for Merry Jane.

This problem soon could be coming to an end; all thanks to this little-known publicly traded company out of Canada...

Ehave, Inc. (OTC - EHVVF)

Ehave is a medical technology company that has created a platform that will bridge the knowledge gap between medical professionals and marijuana education, all done by using a data-driven approach.
It’s platform is able to address several questions that have left physicians hanging. For example:
  • Is cannabis the right therapeutic to prescribe?
  • What is the most effective strain for a particular condition?
  • What is the appropriate dose or delivery method for a particular condition?
  • How does a clinician compare treatment options?
  • How can clinicians ensure that patients are using the product as prescribed?
  • How do patients know their prescription is working the way its supposed to?
  • Do payors have the right reimbursement criteria?
  • Where should licensed producers concentrate their research and development effort
The ehave platform enables users to monitor every step of the cannabis treatment life cycle, from diagnosis and treatment planning to outcomes verification.

Ehave is able to do this through its partnership with MedReleaf, Canada’s leading medical cannabis licensed producer. Ehave Connect enables developers, and ultimately prescribers, a powerful tool that takes the guesswork out of the equation.

This will allow the industry to grow, enabling more accurate and efficient study of medical marijuana and help establish guidelines that physicians are currently missing when prescribing cannabis therapies.

“By 2024, more than 450,000 Canadian patients will be prescribed medical cannabis, creating a market worth more than $1.3 billion, according to Health Canada estimates,”

- Prateek Dwivedi
President and CEO of Ehave
Ehave’s technology will be integrating with MedReleaf’s patient and physician dashboard that is used to establish baseline patient assessments and track patient-reported symptoms by including a panel of clinically-validated surveys into a single digital portal.
In other words…

it’s a game changer.

About Ehave, Inc. (OTC: EHVVF)

Ehave is a Canadian-based company that trades on the over the counter market under the ticker symbol: EHVVF.

The firm builds data-rich tools that improve patient management, diagnosis and treatment.

The Ehave platform was originally designed to address issues of patients suffering from common mental health disorders.

Think about it, doctors are very busy people who see a lot of patients. They often rely on paper records and scribbly notes when evaluating and assessing patients. In a digital age, it’s inefficient.

However, with the ehave platform they get precise details that allow for better decision making. For example, the Ehave platform allows them to record: intake and assignment, assessment, treatment, outcomes verification, and ongoing management.

Ehave works with trusted third-parties to integrate tools into their ecosystem so that clinicians can easily diagnose and treat patients while taking advantage of all the collected data.

Ehave has partnered with Multi-Health Systems to gain access to their library of mental health assessments. This integration into Ehave Connect assists in the diagnostic process and in the development of intervention treatment plans.

The Ehave platform also helps pharmaceutical developers. By using its data management tools, developers are able to reduce errors, save money, cut time, and improve compliance.

Ehave Could Help Solve North America’s Drug Problem

In October of 2017, President Donald Trump called the current opioid crisis a public health emergency.

Now, imagine if medical professionals were able to get accurate and precise information at their fingertips, enabling them to correctly diagnose and treat patients using safer, less addictive medicine. That safer alternative could be marijuana or it could turn out to be something else, but by using the Ehave platform, medical professionals will be able to make decisions based on scientific evidence at their fingertips. Along with a way to track and monitor patients efficiently.

The relationship Ehave has with MedReleaf could potentially change the way that physicians diagnose and prescribe patients medical marijuana.

And you know what… it looks like Ehave has positioned itself take full advantage of this opportunity.

The Canadian Government has decided to allocate $36M to public cannabis education, aimed at teaching the country about safe cannabis consumption.

As more and more people get educated, it’s likely that physicians will embrace marijuana as an alternative to addictive pharmaceutical drugs.

The Hospital for Sick Children is Canada’s most research-intensive hospital and the largest center aimed at improving children’s health. Ehave is proud to have developed ADHD products, in collaboration with the Hospital for Sick Children in Toronto.

Ehave developed MegaTeam, a potential alternative to treat ADHD. Ehave, along with the Hospital for Sick Children in Toronto, developed MegaSonic Action Dash and MegaSong Danger Dive, which are engaging video games with embedded cognitive assessment and rehabilitation tasks for the measurement of cognitive abilities in people with ADHD.

Ehave believes that MegaTeam applications can improve attention, learning, and behavior in individuals with ADHD.

MegaTeam Action Dash was designed to be a more engaging approach to measuring response inhibition and impulse control.

MegaTeam Danger Dive was designed to be a more engaging version to measuring working memory.

Prateek Dwivedi

Chief executive officer

Ehave’s CEO, Prateek Dwivedi brings more than 20 years of tech and healthcare experience to the firm. He was a former VP and CIO at Mount Sinai Hospital in Toronto, where he led a 170+ person team responsible for technology infrastructure.

Additionally, he was instrumental in leading Cancer Informatics at Princess Margaret Hospital at the University Health Network in Toronto. His responsibilities included building a health and research informatics platform, designed to capture and analyze cancer patient data.

It’s this type of leadership that have investors buzzing about Ehave and it’s prospects on executing its objective. In a short period, Ehave has established strategic relationships with MedReleaf, Multi-Health Systems, The Hospital for Sick Children, Pear Therapeutics, and Ontario Brain Institute.

Shares of Ehave, Inc. (OTC: EHVVF) Could Flourish

Canada plans to legalize marijuana in the summer of 2018. In the U.S., 29 states have legalized medical marijuana. However, medical professionals have been hesitant to discuss marijuana as an alternative to prescription drugs because they lack the knowledge.

For example, there are hundreds of strains of marijuana, many aimed at curing specific ailments, most doctors today don’t have that know-how, so they dismiss marijuana as choice to their patients.

The Ehave platform brings data rich tools right to the fingertips of medical professionals. Its platform may enable a more accurate and efficient study of cannabis and help establish guidelines that clinicians can use when prescribing cannabis therapies.

Politically, there appears to be a crackdown on addictive prescription drugs. Cannabis could soon be a widely accepted mainstream alternative to addictive prescription pills. The Ehave technology could be at the forefront, as this transition occurs. By teaming up with MedReleaf, Canada’s leading medically licensed cannabis producer, Ehave has positioned itself to take advantage of this billion-dollar industry.

The company has already shown promise by establishing key relationships with MedReleaf, Multi-Health Systems, The Hospital for Sick Children, Pear Therapeutics, and the Ontario Brain Institute.

Ehave is empowering healthcare professionals and patients with digital solutions to help medical professionals make data-driven decisions, accurate assessments, and personalized patient care. To find out more about Ehave, Inc. (OTC: EHVVF) visit the firm's investor relations page.

According to a statement of ownership from the SEC, it appears that the Eisenberg Family Foundation, has a 6.27% investment in EHVVF. The founder of this organization, Warren Eisenberg, was the co-founder of Bed Bath & Beyond.

Company’s Recent Breaking News

  • Ehave Advances MedReleaf Collaboration with Launch of Digital Patient Intake Portal Portal 3:41 p.m. Nov. 1, 2017
  • Ehave Highlights Solutions to Support and Improve ADHD Treatment During ADHD Awareness Month Portal 3:41 p.m. Nov. 1, 2017
  • Ehave Highlights Recent Developments and Corporate Strategy in Updated Letter to Shareholders Portal 3:41 p.m. Nov. 1, 2017
  • Ehave Announces Launch of the Next Generation of the Ehave Platform and Ehave Connect to Facilitate Rapid Third-Party Content Integration Portal 3:41 p.m. Nov. 1, 2017
  • Ehave Launches Conners® Suite of ADHD Assessment Tools for Ehave Connect Portal 3:41 p.m. Nov. 1, 2017
  • Ehave Announces the Appointment of Dave Goyette as Chief Technology Officer Portal 3:41 p.m. Nov. 1, 2017
This website is a wholly owned subsidiary of Media One LLC, herein referred to as MO LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

PLEASE NOTE WELL: MO LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold MO LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. MO LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and MO LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead MO LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. MO LLC is compliant with the Can Spam Act of 2003. SCS LLC does not offer such advice or analysis, and MO LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.